Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$5.74-7.72%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put PHAT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Operating income improves to profitability by Q3 2026: Operating income: $-85,000.
View ThesisRevenue is growing steadily — about 87% over the past year.
View GrowthManagement screens strong on earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 68% in its worst 12-month stretch.
View RiskPHAT’s revenue growth supports the thesis, though the company remains unprofitable over the past year. Q3 revenue grew 71% year over year, and reported non-GAAP EPS beat consensus. PHAT trades at 2× sales versus a 10× peer median, below its 3× historical multiple. The price reflects less growth than our forecast. The risk is operating income remaining below the Q3 2026 profitability pillar. Our model puts the next-quarter miss probability near 33%. Peer multiples imply a price about 82% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. PHAT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 12 analysts currently covering PHAT (as of Oct 2026).
Based on 6 Wall Street analysts offering 12-month price targets for PHAT in the last 4 months.
Continue this research
Compare PHAT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PHAT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put PHAT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Maintain 2026 revenue guidance of $320-$345 million
Reiterated guidance is below the tracked $320M-$345M range despite a potentially supportive co-pay rollout.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $5.74
The last 12 months of price, then the range of analyst 12-month targets from today’s $5.74.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Advance clinical pipeline with Phase 3 trial for VOQUEZNA in NERD
Advances clinical pipeline with Phase 3 trial for VOQUEZNA.
